Currently, despite a remarkable initial response to B–Raf proto–oncogene, serine/threonine kinase (BRAF) [4,5], and mitogen–activated protein kinase kinase (MEK) [6,7] inhibitors, most cancer patients subsequently relapse due to acquired resistance. Here, MAP2K7 is linked to cancer.